About Beyond Gender UK Evidence
The British evidence, dated and sourced
This site records what the United Kingdom has actually decided about youth gender medicine and sex-based rights: the Cass Review, NHS England, the courts, Parliament and the schools guidance, each with a date and a source.
Purpose
Britain produced the most thorough official examination of youth gender medicine anywhere in the world, and then acted on it. That makes the UK record uniquely useful, and uniquely vulnerable to being misquoted. This site sets it out: what the Cass Review found, what NHS England did, what the High Court, Court of Appeal and Supreme Court ruled, what Parliament legislated and what the Department for Education told schools.
How it is organised
Evidence dossiers each cover one question, from puberty blockers to single-sex spaces. Each begins with key facts, sets out the positions and links to primary sources. The UK timeline runs from the first Tavistock referrals data to the present. The sources page collects the judgments, reports and guidance in one place, quoted from the originals wherever possible.
Standards
Facts and dates first. Interpretation is marked as interpretation. Primary sources are preferred to press reports, and where only a press report exists that is stated. Corrections are made when readers supply a link to the original document.
Point of view and publisher
The site is gender-critical. It regards the Cass Review as sound, the reversal on puberty blockers as overdue, and the For Women Scotland judgment as a restatement of what the Equality Act always meant. It is published by Genspect, the international organisation founded in Ireland in 2021, whose founder Stella O'Malley hosts the Beyond Gender podcast with Mia Hughes and Dr Bret Alderman.
Dossiers on institutions
NHS England, the royal colleges and institutional reversal
England’s institutional change did not begin with the Cass Review, but Cass gave it a formal evidential and administrative centre. For much of the previous decade, the NHS pathway for adolescents who met specialist criteria assumed that puberty suppression could precede masculinising or feminising hormones. NHS England’s 2016 policy provided for cross-sex hormones from “around” age 16 within the Tavistock’s Gender Identity Development Service (GIDS), while describing puberty blockers as part of the available treatment pathway after assessment and pubertal staging (NHS England, 2016). ([england
Gender-critical belief, Forstater and free speech
Forstater v CGD Europe arose from a workplace dispute during the United Kingdom’s 2018 consultation on reform of the Gender Recognition Act 2004. Maya Forstater, then a visiting fellow at CGD Europe, had expressed views on sex, gender identity, women’s rights and proposed self-identification reforms on social media. She contended that biological sex is real, important and immutable, and that it should not be conflated with gender identity.